Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TQB3303 in Advanced Solid Tumors
NCT04275050Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3303 in advanced malignant solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
TQB3303
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT04275050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275050.